Variations in l-selectin ligand expression in the luteal-phase endometrium after final oocyte maturation with human chorionic gonadotropin compared with.

Slides:

Advertisements

Similar presentations

Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T

Advertisements

The impact of luteal phase support on gene expression of extracellular matrix protein and adhesion molecules in the human endometrium during the window.

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Laura Londra, M. D. , Caroline Moreau, M. D. , M. P. H. , Ph. D

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Who requests their sperm donor's identity

Daily physical activity and hot flashes in the Study of Women's Health Across the Nation (SWAN) Flashes Study Carolyn Gibson, M.P.H., M.S., Karen Matthews,

Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D

Michael M. Alper, M.D. Fertility and Sterility

Impact of circulating levels of total and bioavailable serum vitamin D on pregnancy rate in egg donation recipients Alberta Fabris, M.D., Alberto Pacheco,

Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials Ana Cobo, Ph.D., César Diaz, M.D.

Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression

Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy Ewa Nowak-Markwitz,

Effect of the oxytocin antagonist antocin and agonist decomoton on baboon luteal cell production and release of progesterone M. Yusoff Dawood, M.D.,

Medical treatment of ectopic pregnancy: a committee opinion

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D

The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility Alexander M. Quaas, M.D.,

Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.

Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles Tsung-Hsien.

Oocyte cryopreservation

Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review Seema Menon, M.D., John.

Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T

Robert F. Casper, M.D. Fertility and Sterility

Marcus W. Jurema, M. D. , Andrea D. Vieira, M. D

Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain Mohamed A. Bedaiwy,

Effect of pentoxifylline on vascular endothelial growth factor C and flk-1 expression on endometrial implants in the rat endometriosis model Nikos F.

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone

Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.

Modulation of HOXA10 and other markers of endometrial receptivity by age and human chorionic gonadotropin in an endometrial explant model Robin H. Fogle,

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Nitric oxide metabolite production in the human preimplantation embryo and successful blastocyst formation Christopher W. Lipari, M.D., Jairo E. Garcia,

Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

Prospective cohort study of three- versus two-dimensional ultrasound for prediction of oocyte maturity Doron Shmorgun, M.D., Edward Hughes, M.D., Patrick.

David E. Reichman, M. D. , Stacey A. Missmer, Sc. D. , Katharine F

Ri-Cheng Chian, Ph.D., Peter S. Uzelac, M.D., Geeta Nargund, M.D.

Fertility and Sterility

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

Effects of growth hormone and insulin-like growth factor 1 on progesterone production in human luteinized granulosa cells Toshiaki Taketani, M.D., Yoshiaki.

L. Scott, J. Bernsten, K. DeLegge, J. Hill, N. Ramsing

Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D.,

Kayoko Takata, M. D. , Nobuhiko Suganuma, M. D. , Hisae Wada, M. D

Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization David W. Schmidt, M.D.,,

Fertility and Sterility: an evaluation

Upregulation of mRNA expression of vascular endothelial growth factor and its receptors by exogenous human chorionic gonadotropin in cultured oviduct.

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Impact of leuprolide acetate on luteal phase function in women undergoing controlled ovarian hyperstimulation and intrauterine insemination Deirdre A.

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human.

A study of luteal phase expression of inhibin, activin, and follistatin subunits in the endometrium of women with recurrent miscarriage Alka Prakash,

Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study Ahmed Badawy, M.D., Aboubakr.

Daniel R. Grow, M.D., Khosro Iromloo, M.D. Fertility and Sterility

Ongoing pregnancy rates in intrauterine insemination are affected by late follicular- phase progesterone levels Antonio Requena, M.D., María Cruz, Ph.D.,

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

Contact among families who share the same sperm donor

Serum human chorionic gonadotropin level after ovulation triggering is influenced by the patient’s body mass index and the number of larger follicles

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

P-24 Fertility and Sterility Volume 85, Pages S19-S20 (April 2006)

Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization:

Presentation transcript:

Variations in l-selectin ligand expression in the luteal-phase endometrium after final oocyte maturation with human chorionic gonadotropin compared with a gonadotropin- releasing hormone agonist Christopher W. Lipari, M.D., Yulian Zhao, M.D., Ph.D., Jeremy A. King, M.D., Carolyn J. Alexander, M.D., Brandon B. Bankowski, M.D., M.P.H., Tsung-Hsuan Lai, M.D., Jairo Garcia, M.D., Nikos P. Vlahos, M.D. Fertility and Sterility Volume 90, Issue 3, Pages 876-878 (September 2008) DOI: 10.1016/j.fertnstert.2007.06.075 Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

Figure 1 The l-selectin ligand expression and luteal-phase serum E2 and P concentrations in oocyte donors receiving hCG and leuprolide acetate for final oocyte maturation. All values are means ± SE. EHSCORE = epithelial immunostaining score; GHSCORE = glandular immunostaining score. Fertility and Sterility 2008 90, 876-878DOI: (10.1016/j.fertnstert.2007.06.075) Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions